Abstract
Purpose
Previously we have shown that cholesterol-rich microemulsions that bind to LDL receptors have the ability to concentrate in acute myeloid leukemia cells and in ovarian and breast carcinomas. Thus, LDE may be used as a vehicle for drugs directed against neoplastic cells. Indeed, we subsequently showed that when carmustine is associated with LDE the toxicity of the drug is significantly reduced in patients with advanced cancers. The aim of the present study was to verify whether LDE may be taken up by multiple myeloma cells and whether patients with multiple myeloma respond to treatment with LDE associated with carmustine.
Methods
A total of 131 consecutive volunteer patients with recently diagnosed multiple myeloma classified as clinical stage IIIA had their plasma lipid profile determined. LDE plasma kinetics were performed in 14 of them. Cell uptake of LDE and the cytotoxicity of carmustine associated with the emulsion were evaluated in a multiple myeloma cell line. A pharmacokinetic study of LDE-carmustine was performed in three patients. Finally, an exploratory clinical study of LDE-carmustine (carmustine dose 180 mg/m2 body surface every 4 weeks) was performed in seven untreated multiple myeloma patients.
Results
LDL cholesterol was lower in the 131 multiple myeloma patients than in healthy controls and the fractional clearance rate (FCR, in units per minute) in the 14 multiple myeloma patients was twice that in 14 paired healthy control subjects. Moreover, entry of LDE into multiple myeloma cells was shown to be mediated by LDL receptors. Taken together, these findings indicate that LDE may target multiple myeloma. The exploratory clinical study showed that gammaglobulin decreased by 10-70% (mean 36%) after three cycles and by 25-75% (mean 44%) after six cycles. Furthermore, there was amelioration of symptoms in all patients. Cholesterol concentrations increased after treatment, suggesting that the treatment resulted in at least partial destruction of neoplastic cells with receptor upregulation. Side effects of the treatment were negligible.
Conclusions
Because it targets multiple myeloma and, when associated with an antineoplastic agent, produces therapeutic responses in patients with fewer side effects, LDE has the potential for use as a drug vehicle in the treatment of the disease.
Similar content being viewed by others
References
Ades A, Carvalho JP, Graziani SR, Amancio RF, Souen JS, Pinotti JA, Maranhão RC (2001) Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol Oncol 82:84
Attal M, Harousseau JL, Stoppa AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91
Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma resistant to alkylating agents. N Engl J Med 310:1353
Bernardes-Silva H, Toffoletto O, Bortolotto LA, Latrilha MCM, Krieger EM, Pileggi F, Maranhão RC (1995) Malignant hypertension is accompanied by marked alterations in chylomicron metabolism. Hypertension 26:1207
Borba EF, Bonfa E, Vinagre CGC, Ramires JAF, Maranhão RC (2000) Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033
Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232:34
Brown MS, Dana SE, Goldstein JL (1974) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. J Biol Chem 249:789
Desikan R, Barlogie B, Sawyer J (2000) Results of high dose therapy for 1,000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008
Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842
Fine JM, Fine A, Burstein M (1982) Decreased concentration of low density lipoproteins in malignant forms of monoclonal gammopathy. Rev Fr Transfus Immunohematol 25:273
Friedewald WT, Levy RI, Fredrickson DD (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499
Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER (1981) Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139:877
Ginsburg GS, Small DM, Atkinson D (1982) Microemulsions of phospholipids and cholesterol esters. J Biol Chem 257:8216
Ginsberg H, Gilbert HS, Gibson JC, Ngoc-Anh L, Virgil BW (1986) Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med 96:311
Graziani SR, Igreja FAF, Hegg R, Meneghetti C, Brandizzi LI, Barboza R, Amancio RF, Pinotti JA, Maranhão RC (2002) Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol 85:493
Grundy SM, Vega GL, Bilheimer DW (1985) Kinetic mechanisms determine variability in low density lipoprotein levels and rise with age. Arteriosclerosis 5:623
Gueddari N, Favre G, Hachem H, Marek E, Le Gaillard F, Soula G (1993) Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. Biochemie 75:811
Hachem H, Favre G, Ghalim N, Puchois P, Fruchart JC, Soula G (1987) Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 25:675
Harousseau JL, Attal M, Divine M (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French registry on autologous transplantation in multiple myeloma. Blood 85:3077
Henriksson P, Ericsson S, Stege R, Ericsson M, Rudling M, Berglund L, Angelin B (1989) Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 2:1178
Hirata RDC, Hirata MH, Mesquita CH, Cesar TB, Maranhão RC (1999) Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim Biophys Acta 1437:53
Ho YK, Smith GL, Brown MS, Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099
Hungria VTM, Brandizzi LI, Chiattone, Bydlowski SP, Maranhão RC (1999) Metabolism of an artificial emulsion resembling chylomicrons in patients with multiple myeloma. Leuk Res 23:637
Innerarity TL, Mahley RW (1978) Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 17:1440
Leppälä J, Kallio M, Nikula, T, Nikkinen P, Liewendahl K, Jääskeläinen J, Savolainen S, Gylling H, Hiltunen J, Callaway J, Kahl S, Färkkilä M (1995) Accumulation of99mTc-low-density lipoprotein in human malignant glioma. Br J Cancer 71:383
Levin VA, Hoffman W, Weinkam RJ (1978) Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. Cancer Treat Rep 62:1305
Levy Y, Spira G, Brook GJ, Aviram M, Tatarsky I, Carter A (1984) Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies. Postgrad Med J 60:449
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1958) Protein measurement with the folin phenol reagent. J Biol Chem 193:265
Maranhão RC, Garicochea B, Silva EL, Llacer PD, Pileggi FJC, Chamone DAF (1992) Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia. Braz J Med Biol Res 25:1003
Maranhão RC, Cesar TB, Pedroso-Mariani S, Hirata MH, Mesquita CH (1993) Metabolic behavior in rats of a non-protein microemulsion resembling LDL. Lipids 28:691
Maranhão RC, Garicochea B, Silva EL, Llacer PD, Cadena SMS, Coelho IJC, Meneghetti JC, Pileggi FJC, Chamone DAF (1994) Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 54:4660
Maranhão RC, Feres MC, Martins MT, Mesquita CH, Toffoletto O, Vinagre CGC, Gianinni SD, Pileggi F (1996) Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 126:15
Maranhão RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves P, Mesquita CH, Pileggi P (1997) Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to LDL receptors. Lipids 32:627
Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, Couto RD, Schreier S, Buzaid AC (2002) Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol 49:487
Matthews CME (1957) The theory of tracer experiments with 131I-labeled plasma proteins. Phys Med Biol 2:36
Miller NE (1984) Why does plasma low density lipoprotein concentration in adults increase with age?. Lancet 1:263
Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH (1997) Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group Study E2479. Cancer 79:1561
Pinto LB, Wajgarten M, Silva EL, Vinagre CGC, Maranhao RC (2001) Plasma kinetics of a cholesterol-rich emulsion in young, middle-aged and elderly subjects. Lipids 36:1307
Santos RD, Sposito AC, Ventura LI, Cesar LAM, Ramires JAF, Maranhão RC (2000) Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol 85:1163
Santos RD, Ventura LI, Sposito AC, Schreiber R, Ramires JAF, Maranhão RC (2001) The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc Res 49:456
Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y (2001) Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38:S30
Spósito AC, Maranhão RC, Vinagre CGC, Santos RD, Ramires JAF (2001) Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis 154:455
Ueyama Y, Matsuzawa U, Yamashita S, Funahashi T, Sakai N, Nakamura T, Kubo M, Tarui S (1990) Hypocholesterolemic factor from gallbladder cancer cells. Lancet 336:707
Vinagre CG, Stolf NAG, Bocchi E, Maranhão RC (2000) Chylomicron metabolism in patients submitted to cardiac transplantation. Transplantation 69:532
Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier M, Paul C, Peterson C, Rudling M, Soderberg-Reid K, et al (1990) Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci U S A 87:2598
Acknowledgements
This study was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), São Paulo, Brazil (Grant no. 99/01229-2). Dr. Maranhão holds a Research Award from Conselho de Desenvolvimento Científico e Tecnológico (CNPq), Brasilia, Brazil. The authors are grateful to Mr. Renato Barboza for expert technical support.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hungria, V.T.M., Latrilha, M.C., Rodrigues, D.G. et al. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53, 51–60 (2004). https://doi.org/10.1007/s00280-003-0692-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0692-y